
Oncology NEWS International
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Anticancer Drugs From Zeneca in Regulatory Phase of Development
NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogen agent, has received approval for marketing in the United Kingdom for the treatment of advanced prostate cancer. Zeneca has also filed for approval of Casodex in the United States and several other countries, Zeneca president Robert C. Black said at a media briefing.
NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogenagent, has received approval for marketing in the United Kingdomfor the treatment of advanced prostate cancer. Zeneca has alsofiled for approval of Casodex in the United States and severalother countries, Zeneca president Robert C. Black said at a mediabriefing.
Other new anticancer agents from Zeneca in clinical developmentinclude Tomudex, a cytotoxic thymidylate synthase inhibitor forcolorectal cancer, and Arimidex, an oral nonsteroidal aromataseinhibitor for breast cancer.
The company's LHRH agonist analog Zoladex (goserelin acetate),currently marketed as a 3.6 mg implant for prostate cancer, hasbeen recommended for a new indication--palliation of advancedbreast cancer . An NDA has also been filed for a 10.8-mg, 3-monthdepo formulation, Mr. Black said.
Articles in this issue
almost 31 years ago
First Results of Avicidin Trialsalmost 31 years ago
Chemo Patients Often Develop Menstrual Irregularitiesalmost 31 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicalmost 31 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationalmost 31 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseasealmost 31 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialalmost 31 years ago
Ultrasound Breast Screens Useful in Selected Womenalmost 31 years ago
New Roles Forecast for Endocrine Therapyalmost 31 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsalmost 31 years ago
Osteosarcoma Chemo Regimens DebatedNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


































